Zalicus Inc. – Product Pipeline Review – 2012 by GlobalMarketsDirect

VIEWS: 6 PAGES: 83

More Info
									               Zalicus Inc. – Product Pipeline Review – 2012

                                                                                          Reference Code: GMDHC02210CDB
                                                                                                 Publication Date: MAY 2012




Zalicus Inc. – Product Pipeline Review – 2012                                             GMDHC02210CDB / Published MAY 2012
© Global Markets Direct. This report is a licensed product and is not to be photocopied                               Page(1)
Zalicus Inc. – Product Pipeline Review




Table of Contents
Table of Contents ............................................................................................................................................................................... 2
    List of Tables ................................................................................................................................................................................. 5
    List of Figures ................................................................................................................................................................................ 6
Zalicus Inc. Snapshot ......................................................................................................................................................................... 7
    Zalicus Inc. Overview .................................................................................................................................................................... 7
    Key Information ............................................................................................................................................................................. 7
    Key Facts....................................................................................................................................................................................... 7
Zalicus Inc. – Research and Development Overview ......................................................................................................................... 8
    Key Therapeutic Areas .................................................................................................................................................................. 8
Zalicus Inc. – Pipeline Review .......................................................................................................................................................... 10
    Pipeline Products by Stage of Development ............................................................................................................................... 10
    Pipeline Products – Monotherapy ............................................................................................................................................... 11
Zalicus Inc. – Pipeline Products Glance ........................................................................................................................................... 12
    Zalicus Inc. Clinical Stage Pipeline Products ............................................................................................................................... 12
        Phase II Products/Combination Treatment Modalities ............................................................................................................ 12
        Phase I Products/Combination Treatment Modalities ............................................................................................................. 13
    Zalicus Inc. – Early Stage Pipeline Products ............................................................................................................................... 14
        Pre-Clinical Products/Combination Treatment Modalities ....................................................................................................... 14
        Discovery Products/Combination Treatment Modalities.......................................................................................................... 15
Zalicus Inc. – Drug Profiles............................................................................................................................................................... 16
    CRx-102 ...................................................................................................................................................................................... 16
        Product Description................................................................................................................................................................. 16
        Mechanism of Action ............................................................................................................................................................... 16
        R&D Progress ......................................................................................................................................................................... 16
    Oncology Program....................................................................................................................................................................... 17
        Product Description................................................................................................................................................................. 17
        Mechanism of Action ............................................................................................................................................................... 17
        R&D Progress ......................................................................................................................................................................... 17
    Synavive ...................................................................................................................................................................................... 18
        Product Description................................................................................................................................................................. 18
        Mechanism of Action ............................................................................................................................................................... 18
        R&D Progress ......................................................................................................................................................................... 18
    Z160 ............................................................................................................................................................................................ 19
        Product Description................................................................................................................................................................. 19
        Mechanism of Action ............................................................................................................................................................... 19
        R&D Progress ......................................................................................................................................................................... 19
    Z944 ............................................................................................................................................................................................ 20
        Product Description................................................................................................................................................................. 20
        Mechanism of Action ............................................................................................................................................................... 20
        R&D Progress ......................................................................................................................................................................... 20
Zalicus Inc. – Pipeline Analysis ........................................................................................................................................................ 21
    Zalicus Inc. – Pipeline Products by Therapeutic Class ................................................................................................................ 21



Zalicus Inc. – Product Pipeline Review – 2012                                                                                            GMDHC02210CDB / Published MAY 2012
© Global Markets Direct. This report is a licensed product and is not to be photocopied                                                                                                        Page(2)
Zalicus Inc. – Product Pipeline Review



    Zalicus Inc. – Pipeline Products By Target .................................................................................................................................. 23
    Zalicus Inc. – Pipeline Products by Route of Administration........................................................................................................ 24
    Zalicus Inc. – Pipeline Products By Mechanism of Action ........................................................................................................... 25
Zalicus Inc. – Recent Pipeline Updates ........................................................................................................................................... 26
Zalicus Inc. - Dormant Projects ........................................................................................................................................................ 30
Zalicus Inc. - Discontinued Pipeline Products................................................................................................................................... 31
    Discontinued Pipeline Product Profiles ........................................................................................................................................ 31
        CRx-140 .................................................................................................................................................................................. 31
        CRx-139 .................................................................................................................................................................................. 31
        CRx-150 .................................................................................................................................................................................. 31
        CRx-401 .................................................................................................................................................................................. 32
Zalicus Inc. – Company Statement................................................................................................................................................... 33
Zalicus Inc. – Locations And Subsidiaries ........................................................................................................................................ 35
    Head Office.................................................................................................................................................................................. 35
    Other Locations & Subsidiaries ................................................................................................................................................... 35
Zalicus Inc., Recent Developments .................................................................................................................................................. 36
    Zalicus Inc.- Press Release ......................................................................................................................................................... 36
        May 02, 2012: Zalicus Advances Z160 Into Multiple Phase IIa Clinical Trials For Treatment Of Pain .................................... 36
        Apr 30, 2012: Zalicus Completes Patient Enrollment In Phase IIb Clinical Trial Of Synavive In Rheumatoid Arthritis ............ 36
        Mar 05, 2012: Zalicus Completes Phase I Clinical Study With Reformulated Z160 ................................................................ 37
        Feb 15, 2012: University Of British Columbia Researchers Develop New Drugs To Treat Absence Seizures ....................... 38
        Feb 15, 2012: Zalicus Publishes Preclinical Data Of New Ion Channel Compound, Z944 In Science Translational Medicine 38
        Oct 21, 2009: CombinatoRx's Synavive (CRx-102) Maintains Efficacy Throughout 12 Month Phase 2 Knee OA Extension
        Trial ......................................................................................................................................................................................... 39
        Oct 21, 2009: CombinatoRx'S Synavive (CRx-102) Maintains Efficacy Throughout 12 Month Phase 2 Knee OA Extension
        Trial ......................................................................................................................................................................................... 40
        Jun 11, 2009: Neuromed Pharmaceuticals Announces that Merck Terminates Research Collaboration and License
        Agreement for Compounds Targeting N-Type Calcium Channels .......................................................................................... 41
        May 27, 2009: CombinatoRx Reports Positive Phase II Trial Results For CRx-401 ............................................................... 41
Financial Deals Landscape .............................................................................................................................................................. 43
    Zalicus Inc., Deals Summary ....................................................................................................................................................... 43
Zalicus Inc., Pharmaceuticals & Healthcare, Deal Details ................................................................................................................ 45
    Venture Financing ....................................................................................................................................................................... 45
        CombinatoRx Secures $30 Million In Third Round Of Financing ............................................................................................ 45
    Partnerships ................................................................................................................................................................................ 47
        Zalicus And Hydra Biosciences Enter Into Partnership To Develop Ion Channel Product Candidates For Treatment Of Pain
        ................................................................................................................................................................................................ 47
        CombinatoRx Enters Into Research Collaboration With Charley's Fund And THE NASH AVERY ......................................... 49
        Gene Network Sciences Enters Into Research Collaboration Agreement With CombinatoRx ................................................ 51
        CombinatoRx Signs An Agreement With Cystic Fibrosis Foundation Therapeutics................................................................ 52
        CombinatoRx Signs Agreement With Fovea Pharma ............................................................................................................. 53
        CombinatoRx Enters Into Research Agreement With CHDI ................................................................................................... 54
        CombinatoRx Enters Into Co-Development Agreement With ABC2 ....................................................................................... 55
        CombinatoRx Enters Into Research And Development Collaboration Agreement With Spinal Muscular Atrophy Foundation 56
    Merger ......................................................................................................................................................................................... 58



Zalicus Inc. – Product Pipeline Review – 2012                                                                                             GMDHC02210CDB / Published MAY 2012
©Global Markets Direct.. This report is a licensed product and is not to be photocopied                                                                                                          Page(3)
Zalicus Inc. – Product Pipeline Review



         CombinatoRx Completes Merger With Neuromed .................................................................................................................. 58
    Licensing Agreements ................................................................................................................................................................. 61
         Zalicus Extends Licensing Agreement With Novartis Institutes For Oncology Combinations ................................................. 61
         Zalicus Extends Licensing Agreement With Novartis Institutes for BioMedical Research....................................................... 62
         Clinical Data Enters Into License Agreement With CombinatoRx ........................................................................................... 63
         CombinatoRx Enters Into Licensing Agreement With Novartis Institutes For BioMedical Research ....................................... 64
         Angiotech Pharma Extends Licensing Agreement With CombinatoRx ................................................................................... 66
         CombinatoRx Enters Into Licensing Agreement With Fovea Pharma ..................................................................................... 67
         CombinatoRx Enters Into Research And Licensing Agreement With Angiotech Pharma ...
								
To top